Celularity Inc

We are a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related disease. We use novel therapies derived from the post-partum human placenta. Our objective is to meaningfully reduce the duration and severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality towards the end of life. Aging is a major risk factor for many degenerative disorders and diseases across multiple high-value therapeutic areas, including immunology and regenerative medicine. These disorders and diseases involve the progressive loss of function or structure (or both) of affected tissues and organs, driven by underlying cellular dysfunction. These processes directly impact regenerative capacity, healthspan, and overall lifespan. Age-associated immunosenescence and other physiological changes contribute to increased vulnerability to infections, which further exacerbate aging-related decline and are increasingly associated with frailty and adverse clinical outcomes. Aging and longevity are determined by a complex combination of genetic, nongenetic, and environmental factors. While aging is not a disease, it increases vulnerability to disease and is among the most important known risk factors for most chronic diseases. For example, aging is a primary driver of cancer and other chronic conditions. The accumulation of senescent cells in aged tissues is suggested to be a key factor underlying age-related cancer. Age is also a key risk factor for autoimmune disease, with many autoimmune diseases preferentially occurring in the second half of adulthood as immune function declines. These processes are increasingly linked to age-related immune dysregulation. Aging is associated with a progressive degeneration of tissues, resulting in significant impairment on the structure and function of vital organs. Chronic, low-grade systemic inflammation, often referred to as "inflammaging," is characterized by higher levels of circulating pro-inflammatory cytokines driven by cellular damage and senescent cell accumulation. Senescent cells contribute to disease progression by limiting the regenerative capacity of tissue stem cells and inducing the accumulation of cellular damage.